Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 4, 1997, Pages 757-762

  Winters, Mark A ^a,c   Shafer, Robert W ^a   Jellinger, Robert A ^a   Mamtora, Gargi ^b   Gingera, Thomas ^b   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY   (United States)

^b Thermo Fisher Scientific   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; NUCLEOSIDE ANALOG;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION;

EID: 0030892246     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.4.757     Document Type: Article

References (33)

1. Boucher, C. A. B., W. Keulen, T. van Bommel, M. Nijhuis, D. de Jong, M. D. de Jong, P. Schipper, and N. K. T. Back. 1996. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob. Agents Chemother. 40:2404-2409.
2. Cox, S. W., J. Albert, J. Wahlberg, M. Uhlen, and B. Wahren. 1992. Loss of synergistic response to combinations containing AZT in AZT-resistant HIV-1. AIDS Res. Hum. Retroviruses 8:1229-1234.
3. Demeter, L. M., T. Nawaz, G. Morse, R. Dolin, A. Dexter, P. Gerondelis, and R. C. Reichman. 1995. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J. Infect. Dis. 172: 1480-1485.
4. Eron, J. J., Y.-K. Chow, A. M. Caliendo, J. Videler, K. M. Devore, T. P. Cooley, H. A. Liebman, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1993. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob. Agents Chemother. 37:1480-1487.
5. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
6. Gao, W.-Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent antiviral activity and anabolic phosphorylation of 2′-3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
7. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66:7128-7135.
8. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
9. Gu, Z., E. J. Arts, M. A. Parniak, and M. A. Wainberg. 1995. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′-triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92:2760-2764.
10. Holodniy, M., L. Mole, D. Margolis, J. Moss, H. Dong, E. Boyer, M. Urdea, J. Kolberg, and S. Eastman. 1995. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J. Virol. 69:3510-3516.
11. R) in culture (ex) may be unstable with serial passage (P), abstr. I280, p. 255. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Jellinger, R. A., R. W. Shafer, and T. C. Merigan. A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates. J. Infect. Dis., in press.
13. Katzenstein, D. A., S. M. Hammer, M. D. Hughes, H. Gundacker, J. B. Jackson, S. Fiscus, S. Rasheet, T. Elbeik, R. Reichman, A. Japour, T. C. Merigan, and M. S. Hirsch. 1996. Virologic and immunologic markers and clinical outcomes after nucleoside therapy in adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 335:1091-1098.
14. Kavlick, M. F., T. Shirasaka, E. Kojima, J. Pluda, F. Hui, R. Yarchoan, and H. Mitsuya. 1995. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antivir. Res. 28:133-146.
15. Kojima, E., T. Shirasaka, B. D. Anderson, S. Chokekijchai, S. M. Steinbert, S. Broder, R. Yarchoan, and H. Mitsuya. 1995. Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy. J. Infect. Dis. 171:1152-1158.
16. Kozal, M. J., K. Kroodsma, M. A. Winters, R. W. Shafer, B. Efron, D. A. Katzenstein, and T. C. Merigan. 1994. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann. Intern. Med. 121:263-268.
17. Kozal, M. J., R. W. Shafer, M. A. Winters, D. A. Katzenstein, and T. C. Merigan. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-532.
18. Kusumi, K., B. Conway, S. Cunningham, A. Berson, C. Evans, A. K. N. Iversen, D. Colvin, M. V. Gallo, S. Coutre, E. G. Shpaer, D. V. Faulkner, A. deRonde, S. Volkman, C. Williams, M. S. Hirsch, and J. I. Mullins. 1992. Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J. Virol. 66:875-885.
19. Mayers, D. L., A. J. Japour, J.-M. Arduino, S. M. Hammer, R. Reichman, K. F. Wagner, R. Chung, J. Lane, C. S. Crumpacker, G. X. McLeod, L. A. Beckett, C. R. Roberts, D. Winslow, D. Burke, and The RV43 Study Group. 1994. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob. Agents Chemother. 38:307-314.
20. Nijhuis, M., C. A. Boucher, and R. Schuurman. 1995. Sensitive procedure for amplification of HIV-1 RNA using a combined reverse transcription and amplification reaction. BioTechniques 19:178-182.
21. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
22. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, S. Kwok, J. Sninsky, and C. A. B. Boucher. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-1419.
23. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. N. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer III, P. Gupta, S. Rasheed, R. Coombs, M. Katzman, S. Fiscus, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
24. Shafer, R. W., M. A. Winters, R. M. Jellinger, and T. C. Merigan. 1996. Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. J. Infect. Dis. 174:448-449.
25. Shirasaka, T., S. Chokekijchai, A. Yamada, G. Gosselin, J.-L. Imbach, and H. Mitsuya. 1995. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 39: 2555-2559.
26. Simmonds, P., L. Q. Zhang, F. McOmish, P. Balfe, C. A. Ludlam, and A. J. L. Brown. 1991. Discontinuous sequence change of human immunodeficiency virus (HIV) type 1 env sequences in plasma viral and lymphocyte-associated proviral populations in vivo: implications for models of HIV pathogenesis. J. Virol. 65:6266-6276.
27. Smith, M. S., K. L. Koerber, and L. S. Pagano. 1993. Zidovudine-resistant human immunodeficiency virus type 1 genomes detected in plasma distinct from viral genomes in peripheral blood mononuclear cells. J. infect. Dis. 167:445-458.
28. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
29. Tisdale, M., N. R. Parry, D. Cousens, M. H. St. Clair, and L. R. Boone. 1994. Anti-HIV activity of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89), abstr. 182, p. 92. In Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
30. Vartanian, J.-P., A. Meyerhans, B. Åsjö, and S. Wain-Hobson. 1991. Selection, recombination, and G→A hypermulation of human immunodeficiency virus type 1 genomes. J. Virol. 65:1779-1788.
31. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak, B. S. Han, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1. Nature 373:117-122.
32. Winters, M. A., L. B. Tan, D. A. Katzenstein, and T. C. Merigan. 1993. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J. Clin. Microbiol. 31:2960-2966.
33. Zhang, D., A. M. Caliendo, J. J. Eron, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.